Hilt Silvia, Liu Ruiwu, Maezawa Izumi, Rojalin Tatu, Aung Hnin H, Budamagunta Madhu, Slez Ryan, Gong Qizhi, Carney Randy P, Voss John C
Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA, United States.
M.I.N.D. Institute and Department of Pathology and Laboratory Medicine, University of California, Davis, Davis, CA, United States.
Front Chem. 2022 May 26;10:896386. doi: 10.3389/fchem.2022.896386. eCollection 2022.
Several neurodegenerative diseases are driven by misfolded proteins that assemble into soluble aggregates. These "toxic oligomers" have been associated with a plethora of cellular dysfunction and dysregulation, however the structural features underlying their toxicity are poorly understood. A major impediment to answering this question relates to the heterogeneous nature of the oligomers, both in terms of structural disorder and oligomer size. This not only complicates elucidating the molecular etiology of these disorders, but also the druggability of these targets as well. We have synthesized a class of bifunctional stilbenes to modulate both the conformational toxicity within amyloid beta oligomers (AβO) and the oxidative stress elicited by AβO. Using a neuronal culture model, we demonstrate this bifunctional approach has the potential to counter the molecular pathogenesis of Alzheimer's disease in a powerful, synergistic manner. Examination of AβO structure by various biophysical tools shows that each stilbene candidate uniquely alters AβO conformation and toxicity, providing insight towards the future development of structural correctors for AβO. Correlations of AβO structural modulation and bioactivity displayed by each provides insights for future testing . The multi-target activity of these hybrid molecules represents a highly advantageous feature for disease modification in Alzheimer's, which displays a complex, multifactorial etiology. Importantly, these novel small molecules intervene with intraneuronal AβO, a necessary feature to counter the cycle of dysregulation, oxidative stress and inflammation triggered during the earliest stages of disease progression.
几种神经退行性疾病是由错误折叠的蛋白质组装成可溶性聚集体所驱动的。这些“毒性寡聚体”与大量细胞功能障碍和失调有关,然而其毒性背后的结构特征却知之甚少。回答这个问题的一个主要障碍与寡聚体的异质性有关,无论是在结构无序还是寡聚体大小方面。这不仅使阐明这些疾病的分子病因变得复杂,也使这些靶点的可药用性变得复杂。我们合成了一类双功能芪类化合物,以调节淀粉样β寡聚体(AβO)内的构象毒性以及AβO引发的氧化应激。使用神经元培养模型,我们证明这种双功能方法有潜力以强大的协同方式对抗阿尔茨海默病的分子发病机制。通过各种生物物理工具对AβO结构的研究表明,每种芪类候选物都独特地改变了AβO的构象和毒性,为AβO结构校正剂的未来开发提供了见解。每种化合物所显示的AβO结构调节与生物活性之间的相关性为未来测试提供了见解。这些杂合分子的多靶点活性代表了阿尔茨海默病疾病修饰的一个高度有利特征,该病表现出复杂的多因素病因。重要的是,这些新型小分子干预神经元内的AβO,这是对抗疾病进展最早阶段触发的失调、氧化应激和炎症循环的必要特征。